Recce Pharmaceuticals Valuation
Is R9Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of R9Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate R9Q's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate R9Q's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for R9Q?
Other financial metrics that can be useful for relative valuation.
| What is R9Q's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 22.7x |
| Enterprise Value/EBITDA | -6.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does R9Q's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.2x | ||
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
93M1 MPH Health Care | 0.8x | -60.2% | €98.5m |
HIGH Cantourage Group | 27.3x | 38.7% | €58.1m |
2FJ0 Pierrel | 3.4x | n/a | €92.8m |
R9Q Recce Pharmaceuticals | 21.4x | -2.0% | €107.8m |
Price-To-Sales vs Peers: R9Q is expensive based on its Price-To-Sales Ratio (21.4x) compared to the peer average (11.2x).
Price to Earnings Ratio vs Industry
How does R9Q's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: R9Q is expensive based on its Price-To-Sales Ratio (21.4x) compared to the European Pharmaceuticals industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is R9Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 21.4x |
| Fair PS Ratio | 0.5x |
Price-To-Sales vs Fair Ratio: R9Q is expensive based on its Price-To-Sales Ratio (21.4x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.